Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases.
OBJECTIVE
To investigate the association between serum insulin-like growth factor 1 (IGF-1), osteocalcin, and parathyroid hormone (PTH) levels with the etiology and clinical condition of patients with chronic liver disease.


METHODS
Eighty children with hepatocellular damage were divided into 3 groups according to the etiology of disease infection: bilharziasis (9 patients), hepatitis B virus (HBV, 12 patients) and hepatitis C virus (HCV, 29 patients). The Child score index was found as A in 24 patients, B in 22 patients, C in 4 patients. Thirty healthy children served as control group. HBsAg, HBcAbIgM, HBcAbIgG, and anti-HCV were detected using ELISA technique. HCV-RNA was measured by reverse transcription polymerase chain reaction (RT-PCR). Anti-bilharzial antibodies were detected by indirect haem- agglutination test. Liver function tests were performed using autoanalyser. Serum IGF-1, osteocalcin and PTH levels were measured by ELISA technique. Abdominal ultrasonography was also conducted.


RESULTS
Serum IGF-1 level was significantly lower in all patient groups with liver diseases, while serum osteocalcin and PTH levels were significantly elevated in patients with HBV and HCV infections compared with the control group. Serum osteocalcin and PTH concentrations were measured with the severity of liver disease from Child A to C. Child A patients unexpectedly showed significantly reduced IGF-1 levels in comparison to patients staged as Child B or C. Serum osteocalcin level was negatively correlated with albumin (14.7 +/- 0.54 vs 3.6 +/- 0.10, P < 0.05), while that for PTH was positively correlated with total protein (70.1 +/- 2.17 vs 6.7 +/- 0.10, P < 0.05) in patients with HCV infection.


CONCLUSIONS
Low serum IGF-1 level seems to play a critical role in the bone loss in patients with chronic liver disease. Elevated biochemical markers of bone remodeling suggest high-turnover in patients with viral infection and reflect severity of the clinical stage.
Mahdy
Karam A
KA
Medical Biochemistry Department, National Research Centre, Dokki 12311, Cairo, Egypt. karammahdy@yahoo.com
Ahmed
Hanaa H
HH
Mannaa
Fathia
F
Abdel-Shaheed
Azza
A
D000293:Adolescent; D015415:Biomarkers / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004534:Egypt; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008107:Liver Diseases / Q000097:blood* / Q000150:complications*; D008297:Male; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000097:blood* / Q000209:etiology*; D010281:Parathyroid Hormone / Q000097:blood
D015415:Biomarkers; D010281:Parathyroid Hormone; D015675:Osteocalcin; D007334:Insulin-Like Growth Factor I